Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

Cost control and the advancement of its solid Phase III pipeline will be critical to long-term success. Eli Lilly has 7 molecules in Phase III development, 22 molecules in Phase II development and ...

INDIANAPOLIS, Feb. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2022. "2023 is an inflection point for Lilly - a chance ...

Lilly has 11 obesity drugs in its pipeline and wants to develop more ... Eli Lilly will invest $4.5 billion to ... Any new advances could help Lilly become the first trillion ...

We are increasing Eli Lilly’s fair value estimate to $500 from $450 following solid fourth-quarter results with robust sales from diabetes drug Mounjaro and strong pipeline advancements running ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...